Pacpaint: a histology-based deep learning model uncovers the extensive intratumor molecular heterogeneity of pancreatic adenocarcinoma
Charlie Saillard(Laboratoire Procédés et Ingénierie en Mécanique et Matériaux), Jérôme Cros(Université Paris Cité), Armelle Bardier–Dupas(Sorbonne Université), Vinciane Rebours(Hôpital Beaujon), Benoît Schmauch(Owl Research Institute), Cindy Neuzillet, Louis de Mestier(Inserm), Magali Svrcek(Azienda Unita' Sanitaria Locale Di Modena), Aurélie Kamoun(La Ligue Contre le Cancer), Pierre Courtiol, Rémy Nicolle(Centre National de la Recherche Scientifique), F. Delecourt(Inserm), Mikhail Zaslavskiy, Valérie Paradis(Centre National de la Recherche Scientifique), Jean‐Baptiste Bachet(Université Paris Cité), Juan Iovanna(Centre National de la Recherche Scientifique), Pascal Hammel(Université Paris Cité), Jean‐François Emile(Université de Versailles Saint-Quentin-en-Yvelines), Yasmina Kermezli(Centre National de la Recherche Scientifique), Magali Richard(Centre National de la Recherche Scientifique), Olivier Moindrot, Nelson Dusetti(Inserm), Yuna Blum(Centre National de la Recherche Scientifique), Mira Ayadi(IntegraGen (France))
Cited by 64
Related Papers
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
|Blood|2016|1.6k
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|1.3k
Interferon-γ –Receptor Deficiency in an Infant with Fatal Bacille Calmette–Guérin Infection
|New England Journal of Medicine|1996|878